IL6 and neoplasm: In the tested time frame, tumor cytotoxicity (Fig. 2c, red curve) was the most sensitive readout for cibisatamab, with an EC50 38-fold lower than T-cell activation and approximately 145- and 96-fold lower than IL2 and IL6 release, respectively.